Table 2.
Metabolite associations
| Metabolite | Pathway | RVM | RVEDV | RVM/RVEDV | RVEF | VMI | 3D wall stress |
|---|---|---|---|---|---|---|---|
| DHEA-S | Steroid | – | −0.26** | 0.18* | 0.31*** | −0.21** | −0.4, 86.8%* |
| N2DMG | Purine, Guanine | – | 0.18* | −0.17* | −0.28*** | – | 0.34, 73.1%* |
| N1MI | Purine, Hypo-Xanthine/Inosine | – | – | – | −0.21** | – | 0.28, 87.2%* |
| 3H3MG | Mevalonate | – | – | – | −0.25** | 0.18* | 0.32, 81.7%* |
| NAM | Met, Cys, SAM & Tau | – | – | −0.18* | −0.22** | – | 0.31, 81.9%* |
| NFM | Met, Cys, SAM & Tau | – | 0.17* | −0.14* | −0.23** | −0.17* | 0.32, 69.7%* |
| Fumarate | TCA cycle | – | 0.26** | −0.24** | −0.26** | 0.22* | – |
| 1L2EP | Phospholipid | – | – | – | – | – | – |
| SM | Sphingolipid | – | – | – | 0.2* | −0.24** | – |
| NAT | Met, Cys, SAM & Tau | – | 0.23* | −0.17* | −0.18* | – | – |
Adjusted P-value:
<0.05;
<0.01;
<0.001.
The relationship between metabolite concentration and phenotypic variables corrected for false discovery rate (presented as β coefficient with adjusted P-value, including area% for wall stress mapping).
3D, three-dimensional; DHEA-S, dehydroepiandrosterone sulfate; 3H3MG, 3-hydroxy-3-methylglutarate; 1L2EP, 1-linoleoyl-2-eicosapentaenoyl-GPC (18:2/20:5); NAM, N-acetylmethionine; NAT, N-acetyltaurine; NFM, N-formylmethionine; N1MI, N1-methylinosine; N2DMG, N2, N2-dimethylguanosine; RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; RVM, right ventricular mass; RVM/RVEDV, RVM corrected for RVEDV; VMI, ventricular mass index; SM, sphingomyelin (d18:1/20:0, d16:1/22:0); –, not significant.